Project Grant R44AI188587
Award Date 8/7/25
Completion Date 7/31/28
Dollars Obligated $995K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Van Nuys, CA 91423, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Biotherapeutics, Inc., a clinical-stage biotechnology company in Blacksburg, Virginia. The funding will support the development of a novel oral small molecule therapeutic for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease affecting 1.5 million Americans. The company has identified a novel...
- This federal Project Grant award of $2,989,958 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Thomas Jefferson University's Sidney Kimmel Medical College. The grant supports research to delineate the mechanisms by which pyrimidine synthesis promotes systemic autoimmunity in systemic lupus erythematosus (SLE). The research aims to improve understanding of the role of pyrimidine...
- This federal Project Grant award for $3,364,935.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to functionally and mechanistically characterize genetic factors that contribute to the development of systemic lupus erythematosus (SLE). The research aims to elucidate the role of autophagy, a cellular process, in the pathogenesis of SLE, particularly in immune cells and...
- This $256,808 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The University of Washington is conducting this research, which focuses on analyzing altered mRNA splicing in SLE neutrophils and exploring the consequences of these splicing changes, including...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $149,008 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to Cartesian Therapeutics Inc. to develop and evaluate a novel cell therapy for the treatment of systemic lupus erythematosus (SLE). The funding will support a Phase 2A clinical trial and the design of a subsequent randomized, placebo-controlled Phase 2B trial to test "Descartes-08", an RNA-engineered chimeric antigen...
- This $558,045 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate how the enzyme protein phosphatase 2A (PP2A) controls the function of T cells and contributes to the development of systemic lupus erythematosus (SLE). The research aims to determine how PP2A regulates metabolic enzymes involved in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to determine the therapeutic potential of CpG-B oligonucleotides (ODNs) for the management of systemic lupus erythematosus (SLE). The $132,930 award, active from January 2025 to July 2028, will support in vitro and in vivo studies using MRL/lpr and humanized mouse models to investigate how CpG-B ODNs, which mimic bacterial...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) in the amount of $235,500 supports the development of a novel Trispecific Killer Cell Engager (TRIKE) for the treatment of Systemic Lupus Erythematosus (SLE). The objective is to engineer a TRIKE that can effectively engage and activate natural killer (NK) cells with high affinity, thereby facilitating the efficient clearance of pathogenic immune...
- This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...
- The federal Project Grant award of $300,000 was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to Temple University in Philadelphia, PA. The funding supports research focused on understanding the role of the kallikrein-kinin system and its ability to suppress the type I interferon response, which is a hallmark of systemic lupus erythematosus (SLE). The research aims to explore new pathways for interferon suppression and their...